Literature DB >> 34129844

YAP Accelerates Notch-Driven Cholangiocarcinogenesis via mTORC1 in Mice.

Xinjun Lu1, Baogang Peng2, Ge Chen3, Mario G Pes4, Silvia Ribback5, Cindy Ament6, Hongwei Xu7, Rajesh Pal6, Pedro M Rodrigues8, Jesus M Banales9, Matthias Evert6, Diego F Calvisi6, Xin Chen10, Biao Fan11, Jingxiao Wang12.   

Abstract

Intrahepatic cholangiocarcinoma (iCCA) is a lethal malignant neoplasm with limited therapeutic options. Previous studies have found that Notch1 overexpression alone suffices to induce iCCA in the mouse, albeit after long latency. The current study found that activation of the Yes-associated protein (Yap) proto-oncogene occurs during Notch1-driven iCCA progression. After co-expressing activated Notch1 intracellular domain (Nicd) and Yap (YapS127A) in the mouse liver, rapid iCCA formation and progression occurred in Nicd/Yap mice. Mechanistically, an increased expression of amino acid transporters and activation of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway was detected in Nicd/Yap mouse liver tumors. Significantly, the genetic deletion of Raptor, the major mTORC1 component, completely suppressed iCCA development in Nicd/Yap mice. Elevated expression of Notch1, YAP, amino acid transporters, and members of the mTORC1 pathway was also detected ubiquitously in a collection of human iCCA specimens. Their levels were associated with a poor patient outcome. This study demonstrates that Notch and YAP concomitant activation is frequent in human cholangiocarcinogenesis. Notch and YAP synergize to promote iCCA formation by activating the mTORC1 pathway.
Copyright © 2021 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34129844      PMCID: PMC8420864          DOI: 10.1016/j.ajpath.2021.05.017

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   5.770


  63 in total

1.  Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.

Authors:  Shanshan Zhang; Xinhua Song; Dan Cao; Zhong Xu; Biao Fan; Li Che; Junjie Hu; Bin Chen; Mingjie Dong; Maria G Pilo; Antonio Cigliano; Katja Evert; Silvia Ribback; Frank Dombrowski; Rosa M Pascale; Antonio Cossu; Gianpaolo Vidili; Alberto Porcu; Maria M Simile; Giovanni M Pes; Gianluigi Giannelli; John Gordan; Lixin Wei; Matthias Evert; Wenming Cong; Diego F Calvisi; Xin Chen
Journal:  J Hepatol       Date:  2017-07-19       Impact factor: 25.083

2.  Hes1 Is Essential in Proliferating Ductal Cell-Mediated Development of Intrahepatic Cholangiocarcinoma.

Authors:  Tomoaki Matsumori; Yuzo Kodama; Atsushi Takai; Masahiro Shiokawa; Yoshihiro Nishikawa; Tomonori Matsumoto; Haruhiko Takeda; Saiko Marui; Hirokazu Okada; Tomonori Hirano; Takeshi Kuwada; Yuko Sogabe; Nobuyuki Kakiuchi; Teruko Tomono; Atsushi Mima; Toshihiro Morita; Tatsuki Ueda; Motoyuki Tsuda; Yuki Yamauchi; Katsutoshi Kuriyama; Yojiro Sakuma; Yuji Ota; Takahisa Maruno; Norimitsu Uza; Hiroyuki Marusawa; Ryoichiro Kageyama; Tsutomu Chiba; Hiroshi Seno
Journal:  Cancer Res       Date:  2020-10-16       Impact factor: 12.701

3.  Axis inhibition protein 1 (Axin1) Deletion-Induced Hepatocarcinogenesis Requires Intact β-Catenin but Not Notch Cascade in Mice.

Authors:  Yu Qiao; Jingxiao Wang; Eylul Karagoz; Binyong Liang; Xinhua Song; Runze Shang; Katja Evert; Meng Xu; Li Che; Matthias Evert; Diego F Calvisi; Junyan Tao; Bruce Wang; Satdarshan P Monga; Xin Chen
Journal:  Hepatology       Date:  2019-04-11       Impact factor: 17.425

Review 4.  Cholangiocarcinoma - evolving concepts and therapeutic strategies.

Authors:  Sumera Rizvi; Shahid A Khan; Christopher L Hallemeier; Robin K Kelley; Gregory J Gores
Journal:  Nat Rev Clin Oncol       Date:  2017-10-10       Impact factor: 66.675

5.  A Runaway PRH/HHEX-Notch3-Positive Feedback Loop Drives Cholangiocarcinoma and Determines Response to CDK4/6 Inhibition.

Authors:  Kevin Gaston; Padma-Sheela Jayaraman; Philip Kitchen; Ka Ying Lee; Danielle Clark; Nikki Lau; Jomnarong Lertsuwan; Anyaporn Sawasdichai; Jutamaad Satayavivad; Sebastian Oltean; Simon Afford
Journal:  Cancer Res       Date:  2019-12-16       Impact factor: 12.701

Review 6.  Targeting amino acids transporters (SLCs) to starve cancer cells to death.

Authors:  Yann Cormerais; Milica Vucetic; Jacques Pouysségur
Journal:  Biochem Biophys Res Commun       Date:  2019-12-17       Impact factor: 3.575

7.  Deregulation of Hippo kinase signalling in human hepatic malignancies.

Authors:  Hua Li; Andy Wolfe; Seth Septer; Genea Edwards; Xiaobo Zhong; Ahmad Bashar Abdulkarim; Sarangarajan Ranganathan; Udayan Apte
Journal:  Liver Int       Date:  2011-10-20       Impact factor: 5.828

8.  Cholangiocarcinomas can originate from hepatocytes in mice.

Authors:  Biao Fan; Yann Malato; Diego F Calvisi; Syed Naqvi; Nataliya Razumilava; Silvia Ribback; Gregory J Gores; Frank Dombrowski; Matthias Evert; Xin Chen; Holger Willenbring
Journal:  J Clin Invest       Date:  2012-07-17       Impact factor: 14.808

Review 9.  Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine.

Authors:  Iván M Moya; Georg Halder
Journal:  Nat Rev Mol Cell Biol       Date:  2019-04       Impact factor: 94.444

Review 10.  Amino acid transporters: Emerging roles in drug delivery for tumor-targeting therapy.

Authors:  Ling Zhang; Chengguang Sui; Wenhan Yang; Qiuhua Luo
Journal:  Asian J Pharm Sci       Date:  2020-03-05       Impact factor: 6.598

View more
  2 in total

1.  The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease.

Authors:  Antonio Cigliano; Shanshan Zhang; Silvia Ribback; Sara Steinmann; Marcella Sini; Cindy E Ament; Kirsten Utpatel; Xinhua Song; Jingxiao Wang; Maria G Pilo; Fabian Berger; Haichuan Wang; Junyan Tao; Xiaolei Li; Giovanni M Pes; Serena Mancarella; Gianluigi Giannelli; Frank Dombrowski; Matthias Evert; Diego F Calvisi; Xin Chen; Katja Evert
Journal:  J Exp Clin Cancer Res       Date:  2022-06-03

2.  Activation of the Unfolded Protein Response (UPR) Is Associated with Cholangiocellular Injury, Fibrosis and Carcinogenesis in an Experimental Model of Fibropolycystic Liver Disease.

Authors:  Chaobo Chen; Hanghang Wu; Hui Ye; Agustín Tortajada; Sandra Rodríguez-Perales; Raúl Torres-Ruiz; August Vidal; Maria Isabel Peligros; Johanna Reissing; Tony Bruns; Mohamed Ramadan Mohamed; Kang Zheng; Amaia Lujambio; Maria J Iraburu; Leticia Colyn; Maria Ujue Latasa; María Arechederra; Maite G Fernández-Barrena; Carmen Berasain; Javier Vaquero; Rafael Bañares; Leonard J Nelson; Christian Trautwein; Roger J Davis; Eduardo Martinez-Naves; Yulia A Nevzorova; Alberto Villanueva; Matias A Avila; Francisco Javier Cubero
Journal:  Cancers (Basel)       Date:  2021-12-24       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.